|Bid||39.04 x 900|
|Ask||39.12 x 1400|
|Day's Range||38.78 - 39.88|
|52 Week Range||17.60 - 71.70|
|Beta (3Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.88|
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 15. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $3.71 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Oral Plenary Presentation Receives SGO Presidential Award
LOS ANGELES-- -- Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved indication resulted in a 34% reduction in the risk of invasive disease recurrence or death versus placebo after patients completed one year of therapy ...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
The pharmaceutical company may have proved Wall Street wrong, but it has a long way to go to reach its full potential -- and that's a good thing for investors.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Puma Biotechnology earnings for the fourth quarter of 2018 have PBYI stock soaring on Friday.Source: Shutterstock Puma Biotechnology (NASDAQ:PBYI) reported losses per share of 32 cents for the fourth quarter of the year. This is better than the company's losses per share of $1.03 from the same period of the year prior. It was also a major boon to PBYI stock by beating out Wall Street's losses per share estimate of 77 cents for the quarter.Net loss reported by Puma Biotechnology for the fourth quarter of 2018 was $30.70 million. This is a narrower net loss than the company's $64.10 million that was reported in the fourth quarter of 2017.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOperating loss reported by Puma Biotechnology for the fourth quarter of the year comes in at $18.60 million. The pharmaceutical company reported an operating loss of $63.60 million during the same time last year.Puma Biotechnology earnings for the fourth quarter of 2018 also includes revenue of $71.10 million. This is a massive increase over the company's revenue of $21.60 million for the fourth quarter of the previous year. It is also a blessing to PBYI sock by coming in above analysts' revenue estimate of $53.50 million for the period. * 9 Best Stocks to Buy on U.S.-China Trade Optimism The strong revenue growth in the Puma Biotechnology earnings report fourth quarter of the year is due to Nerlynx sales. This is the company's first commercial product. Its sales account for $61.10 million of the company's revenue during the quarter.PBYI stock was up 41% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results appeared first on InvestorPlace.
Puma Biotechnology Inc (NASDAQ: PBYI ) announced fourth-quarter results and 2019 guidance Thursday that were ahead of expectations, boosting confidence in Nerlynx achieving a global product revenue estimate ...
Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2018, compared to the fourth quarter and full year 2017.
Puma Biotechnology (NYSE: PBYI ) will be releasing its next round of earnings this Thursday, Feb. 28. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement. Earnings ...
Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.